ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: CT Scanning Of The Brain Subject Of Consensus Development Conference; CCI Plans Congress Events

July 10, 1981

BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma

March 25, 2011

NCI Evaluating PDQ Evaluation

September 1, 1989

Phase III Kyprolis Trial Fails OS Primary Endpoint

August 29, 2014

New Chairman Of Core Grant Review Committee Has Some Advice for Applicants

May 5, 1978

NCI is developing review criteria for a Cancer Center Loan Program that would provide $200 million in loans for capital improvements to qualified centers. NCAB member Eric Lander criticizes limited discussion, “lack of vision” for the loan program.

June 18, 2004